Greater Twin Cities Metro
U of M – Clinical Trials
(1 of 6) For the Newly Diagnosed:
- The JAKPOT Study is recruiting participants ages 12-35 within 100 days of their T1D diagnosis with an A1C <10%. TrialNet researchers are testing two different treatments- abrocitinib and ritlecitinib-to see if either or both can preserve insulin production in people newly diagnosed with type 1 diabetes. Researchers believe these JAK inhibitors may be able to calm the immune system’s attack on cells that make insulin, while also reducing stress to these cells.
- Ages: 12-35, newly diagnosed
- Contact: Kali Johnson, 612-624-6682, joh13933@umn.edu
(2 0f 6) For the Newly Diagnosed:
- The T1D RELAY study is recruiting participants ages 8-45 within 100 days of diagnosis. TrialNet is testing rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extend insulin production in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D). Each therapy has a history of safety and effectiveness. Rituximab-pvvr is FDA-approved to treat several autoimmune diseases, including Rheumatoid Arthritis (RA). Abatacept is FDA approved to treat adult Rheumatoid Arthritis, as well as Juvenile Idiopathic Arthritis (JIA) in children as young as six.
- Ages: 8-45, newly diagnosed
- Contact: Beth Pappenfus 612-624-2922, papp0086@umn.edu
(3 of 6) For those with a family history of T1D:
- TrialNet screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Eligible participants are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D, between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D, and have NOT been diagnosed with T1D.
(4 of 6) For adults with T1D:
- FAM (Follower, Action Plan, and Remote Monitoring) Intervention to Reduce Severe Hyperglycemia in Adults With Type 1 Diabetes Mellitus at Risk for Diabetic Ketoacidosis (DKA).
(5 of 6) For adults with T1D:
- DREAM Study – Diabetes related to Acute Pancreatitis and its mechanisms.
- Ages: 18-75
- Contact: Heather Hodgkins, 612-626-5293
(6 of 6) For adults with T1D:
- Dream Study – Diabetes Related to Acute Pancreatitis and its Mechanisms: Metabolic Outcomes Using Novel CGM metrics.
- Ages: 18-75
- Contact: Heather Hodgkins, 612-626-5293
Rochester, Minnesota
Mayo Clinic – Clinical Trials
(1 of 1) For Newly Diagnosed Teens and Preteens:
- R-5280 in Newly Diagnosed Patients with Type 1 Diabetes
Purpose: Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
Western Minnesota, North Dakota and South Dakota
Sanford – Clinical Trials
(1 of 4) For Sanford Health Patients under the age of 8:
- Pledge Study- Sanford Health Patients Only – Prevention
Early Detection of T1D and Celiac Disease
Ages: <8
Contact: Ann Mays, Ann.Mays@sanfordhealth.org
(2 of 4) For children of all ages:
- General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery Study
(3 of 4) For those with a family history of T1D:
- TrialNet screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Eligible participants are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D, between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D and have NOT been diagnosed with T1D.
- Location: In home or lab test kit
- Ages: 2.5 -45 or 2.5 to 20 depending on above criteria
- Contact: Ann Mays, Ann.Mays@sanfordhealth.org
(4 of 4) For the Newly Diagnosed:
- The T1D RELAY study is recruiting participants ages 8-45 within 100 days of diagnosis. TrialNet is testing rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extend insulin production in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D). Each therapy has a history of safety and effectiveness. Rituximab-pvvr is FDA-approved to treat several autoimmune diseases, including Rheumatoid Arthritis (RA). Abatacept is FDA-approved to treat adult Rheumatoid Arthritis, as well as Juvenile Idiopathic Arthritis (JIA) in children as young as six.
Virtual Clinical Trials
(1 of 4) For T1Ds ages 12-19:
- The USF Mindfulness App study is recruiting participants ages 12—19 living with T1D for at least 6 months. The University of South Florida is conducting the study to learn more about mindfulness for adolescents with T1D.
- Age: 12-19
- Contact: Nicole Rios, con-mindfulness@usf.edu
(2 of 4) For female-identifying T1Ds ages 15-30 experiencing disordered eating:
- The Diabetes Body Acceptance Project is conducting a research study comparing two programs designed to improve body acceptance, reduce body image concerns, and reduce disordered eating behaviors. Female-identifying individuals between the ages of 15-30 with T1D who have body image concerns and/or struggle with disordered eating behaviors are invited to participate. Depending on the program you are randomized to you will attend weekly one-hour groups for 6 weeks (virtual for our chapter area) or watch one hour of videos each week.
(3 of 4) For T1Ds diagnosed at least 3 months ago and use a CGM:
- The University of Oregon is conducting an online study that aims to better understand the experience of people living with T1D in relation to support and resources. The study is looking for individuals who have been diagnosed for at least 3 months and wear a CGM.
- Age: Any
- Contact: https://tinyurl.com/survey/fordiabetes
(4 of 4) For T1Ds, loved-ones, and supporters:
- The T1D Exchange Registry is a research study, conducted over time, for individuals with type 1 diabetes and their supporters. Participants volunteer to provide their data for research (for example, by answering questions in annual surveys). Once enrolled, Registry participants can sign up for other studies on various topics related to type 1 diabetes.
Meet your Clinical Trials Education Volunteers:
Angie Grant – anggrant@hotmail.com
Debbie Evans – debbieaevans1@gmail.com
Updated: 2.6.2025
